In a review by Fintini et al., six patients with PWS and concomitant diabetes were treated with GLP-1 RAs, liraglutide (1.2 – 1.8 mg daily) in four patients and exenatide (20 mcg daily) in two patients, showing only a tendency for BMI and waist circumference reduction after 24 months of treatment (36). The gene discussed is GLP1R; the disease is Prader-Willi syndrome.